tissue distribution of recipient mHA may form the basis for segregating the GVHD and GVL response: while many mHA have a ubiquitous tissue distribution, some are restricNew understanding of the alloresponse following bone marrow transplantation supports the possibility that the ted to lymphoid and myeloid lineages. It is thus likely that within the specclones recognizing CML cells preferentially used V␤5, V␤6/7 while clones recognizing both CML and PHA trum of alloresponses to mHA, T cell subsets exist with a specific TCR corresponding to antigens expressed only on blasts or only PHA blasts preferentially used V␤3 and V␤8. It may therefore be possible to identify in vitroleukemia cells of myeloid lineage. In order to test whether TCR V␤ restriction could serve generated myeloid leukemia-restricted donor T cells by their pattern of V␤ usage. TCR V␤ antibodies could as a basis for selecting leukemia-restricted T cell clones to confer GVL after BMT, we examined V␤ usage in allorethus be used to select and expand leukemia-restricted donor T cells for transfusion after BMT to specifically acting T cell clones raised against chronic myeloid leukemia (CML). We showed that myeloid-restricted T cell enhance the GVL response.
A continuing challenge in the field of allogeneic bone marrow transplantation (BMT) is to prevent the unfavorable Materials and methods alloreaction which leads to graft-versus-host disease (GVHD) while conserving a graft-versus-leukemia (GVL)
Cell separation effect.
1 After BMT, GVHD and GVL are initiated by major and minor histocompatibility antigens (mHA) of the recipiPeripheral blood mononuclear cells (PBMC) were obtained ent, stimulating an alloresponse by donor T cells. 2, 3 While by Ficoll-Hypaque density gradient separation of blood GVHD is usually associated with a GVL response, 4 a GVL from BMT donors and recipients. effect can occur in the absence of clinical GVHD. For CML cells were purified by depleting T and B lymphoexample, remission of leukemia relapsing after BMT can cytes with CD2 and CD19 antibody-coated magnetic beads be induced by donor lymphocyte transfusions without con-(Dynal, Oslo, Norway). The depleted fraction (quantitated comitant GVHD; 5 patients not developing GVHD who by flow cytometry) contained less than 10% CD3 + T cells receive T-replete BMT, have a lower relapse rate than those and no measurable CD20 + B cells. T lymphoblasts from receiving a T-depleted BMT.
6 It has been proposed that the CML patients were prepared by culturing T cells with phytohemagglutinin-P (PHA-P; Difco Lab, Detroit, MI, USA) at 2 g/ml as previously described. 4 irradiated CML cells from the original stimulator, and usage using a panel of antibodies with specificities against cultured in complete medium with IL-2 (100 U/ml) and 11 of the V␤ families. Some presumed clones (v2, v4, v52, 20% T cell growth factor (TCGF; Biotest, NY, USA) as v57, v61) expressed more than one V␤ type indicating the previously described.
14 After 7-10 days, wells with prolipresence of more than one clone. One clone (v29) did not ferating cells were transferred to 96-well round-bottomed mark with any of the V␤ antibodies used (Table 1 ). plates and then to 24-well plates. Cells were continuously cultured for 2-3 months with periodic restimulation by the Pattern of TCR V␤ usage and specificity of clones original CML cells. One hundred and twenty-two clones were obtained, 78 of which survived in culture long enough Eighteen examples of clones with different specificities to study. The cloning efficiency was 12% at 0.3 cell/well were randomly selected to define V␤ usage. Although there (ie 12 clones were obtained for every 100 wells plated).
was some diversity, clones showed a distinct pattern of V␤ preference (Table 1) . Clones responding to CML showed preferential use of the V␤5 (clone v4, V13, v49, v51, v55, 3 H-thymidine incorporation assay v57, v59, v60) , V␤6/7 (clone v54, v57) and V␤13 (clone Triplicate cultures of 10 3 -10 4 T cells/well were incubated v4), and absent V␤3, V␤8 and V␤12. Clones responding with 5 × 10 4 /well irradiated CML cells or PHA blast for only to PHA blasts used V␤8 (clone v14, v17) and V␤12 48 h in 96-well round-bottomed plates as previously (clone v37) families. Clones with dual reactivity showed a described.
14 Responder cells alone and stimulator cells mixed pattern of single use of V␤3 (clone v25), V␤5 (clone alone served as baseline proliferation controls.
3 H-incorporv50), and multiple use of V␤5, V␤8 (clone v52) and ation was determined using a scintillation beta-counter as V␣12.1 (clone v2). Figure 1 shows examples of three clone mean count per minute (c.p.m.) (Wallac, Turkü , Finland).
types and their corresponding proliferative response to T cell response was measured as a proliferation index (PI):
CML cells or PHA blasts. Clone v13 was further studied PI = total stimulated c.p.m./total baseline c.p.m.
against a panel of HLA-DR1-matched myeloid and lymphoid targets. The clone proliferated in response to another CML stimulator (HLA A3; B7,B56; DR1,DR15; DQ5, Flow cytometry analysis of cell phenotype DQ6) and a normal bone marrow stimulator (HLA A3; B7,B56; DR1,DR15; DQ5,DQ6) but not to PHA blasts Approximately 5 × 10 4 cells were stained with 10 l of from the same individuals ( Figure 2 ). This pattern of monoclonal antibody (MoAb) on ice for 30 min. After response suggests that the clone recognized myeloidwashing in PBS, cells were analyzed using flow cytometry restricted rather than leukemia-specific antigens. (Becton Dickinson, San Jose, CA, USA). Either FITC-or PE-conjugated MoAb against CD3, CD4, CD8, CD13, CD20, CD33, CD56 (ImmunoTech, Marseille, France) Discussion were used. A TCR FITC-conjugated MoAb kit (T cell Diagnostics, Woburn, MA, USA) with specificities against
The separation of GVHD and GVL reactions is a central V␤3. 1, 5.1, 5.2, 5.3, 6/7, 8, 12, 13.1, 13.3 and V␣2, 12.1 challenge in the treatment of hematological malignancies was used for TCR analysis. Cells were first incubated with by allogeneic BMT. 1 Current attempts to confer GVL with-10 l of mouse IgG for 5 min to block nonspecific binding, out GVHD include CD4 +15 or CD8 +16 T cell subset then 5-7 l of the specific V␤ MoAb was added to each depletion, accurate dosing of T cells 17 and delayed addtube for a further 30 min.
back of lymphocytes following T cell-depleted BMT.
18
While the incidence and severity of GVHD can be significantly reduced by these manipulations, the GVL effect is Results at best not superior to that observed in unmanipulated BMT and their successful application may be limited to HLASpecificity of T cell clones matched donor transplants for CML. [15] [16] [17] [18] In this study we investigated the possibility of separating Seventy-eight clones were screened for tissue-specificity by measuring 3 H-incorporation after incubation with CML GVHD from GVL in BMT for myeloid leukemias by studying T cell tissue-restricted responses and determining the cells or PHA blasts from the original stimulator. Clones were considered to exhibit a significant response if the PI pattern of antigen receptor usage. We argue that the identification of a restricted TCR usage against the leukemia cells was Ͼ3. Thirty-two clones proliferated in response to both PHA blasts and CML cells, 19 to CML alone, and four to would make possible the adoptive transfer of donor T cells with specific reactivity against myeloid leukemias to PHA blasts alone. The remaining 23 clones had varying 
A positive response was defined as a proliferation index (PI) Ͼ3× background. Phenotype was considered to be negative when Ͻ5% of the cells stained with the antibody. enhance GVL after BMT. We used a one-antigen mistoward the generation of more CML-than PHA blastreacting clones may reflect the use of a stimulator enriched matched stimulator-responder sibling pair to generate antirecipient T cell clones. The majority of the clones reacted for CML cells. In 18 clones studied, several distinct patterns of V␤ usage corresponding to the functional specito both myeloid and lymphoid cell stimulation, consistent with previous in vitro cloning studies. 7, 12, 13 While the dual ficity of the T cell clones were identified. In comparison with the V␤ repertoire of unstimulated responder cells, specificities of the presumed clones could in some cases be attributed to multiple clones contained in the culture, some there was preferential selection of V␤5, V␤6/7 or V␤13 in myeloid responding clones and V␤3, V␤8 or V␤12 for may have recognized the same antigen expressed on both myeloid and lymphoid cells in a manner previously PHA blast-responding clones. Since at least two of the clones with dual reactivity to CML and PHA blasts were described for ubiquitously expressed mHA.
3,7 The bias method could selectively enhance GVL reactivity by permitting the safe transfusion of large numbers of leukemiarestricted T cells on repeated occasions. This would be of particular use in HLA partially matched BMT where as few as 10 6 unselected donor lymphocytes can cause fatal GVHD. 21 These preliminary results confirm in principle that it is feasible to select alloreactive T cells with restricted activity against myeloid tissues. However, further screening against other target cells such as keratinocytes would be required to rule out the possibility that T cells of the selected TCR V␤ repertoire do not possess reactivity that can cause GVHD. understanding and using the alloimmune response to treat rent clinical approaches to separate GVL and GVHD, this
